Special Issue

Plasmid DNA for Gene Therapy and DNA Vaccine Applications

Message from the Guest Editor

Dear Colleagues, In recent years there has been an increased interest in plasmid DNA as a vector for gene therapies and DNA vaccines against infectious, acquired, and genetic diseases, including cancer and COVID-19, Additionally, plasmids are used for the production of viral particles intended for viral gene and oncolytic therapy. With the recent event of artificial gene synthesis methods, the assembly of new plasmids has become easier than ever. Plasmids can be designed to encode for various therapeutic targets, vaccine antigens, therapeutic antibodies, shRNA molecules, elements of CRSPR/Cas9 systems, viral vector elements, etc. Additionally, expression cassettes can now be easily tweaked and codon-optimized for higher and more targeted expression, and bacterial backbones minimized for more efficient and safer plasmid production. However, there are still some challenges that need to be overcome to achieve the widespread application of plasmid DNA therapeutics. This Special Issue welcomes research papers dealing with all aspects of gene therapy and DNA vaccine applications of plasmid DNA. Review articles on the related topics are also welcomed.

Guest Editor

Dr. Urska Kamensek

Department of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, SI-1000 Ljubljana, Slovenia

Deadline for manuscript submissions

closed (31 May 2023)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/112140

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

